Back to News
Market Impact: 0.25

TMO Factor-Based Stock Analysis

TMOSPYNDAQ
Company FundamentalsAnalyst InsightsHealthcare & Biotech
TMO Factor-Based Stock Analysis

According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) is rated highly (62%) using their John Neff-inspired Low PE Investor model, which favors firms with persistent earnings growth trading at a discount. While TMO passes criteria for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, it fails the P/E ratio and total return/PE tests within the strategy, indicating mixed signals based on Neff's value-oriented approach.

Analysis

Thermo Fisher Scientific Inc. (TMO), a large-cap growth stock in the Medical Equipment & Supplies industry, receives a 62% rating from Validea's Low PE Investor model, which is based on John Neff's strategy. This model prioritizes companies demonstrating persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield. A 62% score suggests some level of interest from the strategy, though it falls short of the 80% threshold for notable interest and the 90% mark for strong interest. TMO exhibits strength in several fundamental areas according to this model, passing criteria for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence. However, it fails the P/E ratio and total return/PE tests, indicating that from the perspective of this specific value-oriented strategy, its current valuation does not meet the desired discount criteria despite its positive growth and cash flow characteristics. This presents a mixed assessment where underlying operational strengths are acknowledged but are counterbalanced by valuation concerns within the Neff framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
SPY0.00
TMO0.00

Key Decisions for Investors

  • Investors should weigh Thermo Fisher Scientific's strong fundamental performance, particularly in EPS growth, sales growth, and free cash flow, against its current valuation metrics which do not align with the John Neff Low PE Investor model's discount criteria.
  • Given the mixed signals, with a 62% rating indicating only moderate alignment with the Neff strategy, investors prioritizing deep value based on this specific model might exercise caution or await a more favorable entry point concerning P/E and total return/PE ratios.
  • Consider incorporating analysis from other valuation methodologies or growth-focused strategies to form a comprehensive view, as the Neff model's specific focus on low P/E might not fully capture TMO's profile as a large-cap growth stock.